Kbc Group Nv Arcutis Biotherapeutics, Inc. Transaction History
Kbc Group Nv
- $32.2 Billion
- Q1 2025
A detailed history of Kbc Group Nv transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 5,368 shares of ARQT stock, worth $80,036. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,368Holding current value
$80,036% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
226Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Suvretta Capital Management, LLC New York, NY11.4MShares$170 Million6.61% of portfolio
-
Jennison Associates LLC11.4MShares$169 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$164 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$131 Million7.34% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$129 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $897M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...